Author: Chen, Kuan-Hsuan; Wang, Sheng-Fan; Wang, Szu-Yu; Yang, Yi-Ping; Wang, Mong-Lien; Chiou, Sih-Hwa; Chang, Yuh-Lih
Title: Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019 Cord-id: rtvbf6aw Document date: 2020_8_17
ID: rtvbf6aw
Snippet: As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimo
Document: As the coronavirus disease 2019 (COVID-19, also called severe acute respiratory syndrome coronavirus-2) outbreak accelerates, vigorous and diverse efforts were made in developing treatment strategies. In addition to direct acting agents, increasing evidence showed some potential adjuvant therapies with promising efficacy against COVID-19. These therapies include immunomodulators (i.e. intravenous immunoglobulin, thymosin α-1, interleukin [IL]-6, tocilizumab, cyclosporine, thalidomide, fingolimod), Chinese medicines (i.e. glycyrrhizin, baicalin, Xuebijing), anti–vascular endothelial growth factors (bevacizumab), estrogen modulating drugs, statins, and nutritional supplements (i.e. vitamins A, B, C, D, E and zinc). This article reviewed the pharmacological development of potential adjuvants for COVID-19 treatment.
Search related documents:
Co phrase search for related documents- active component and acute lung injury: 1
- active component and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- active component and administration route: 1
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- acute ards respiratory distress syndrome and adjuvant treatment: 1, 2, 3, 4
- acute ards respiratory distress syndrome and administration route: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
- acute ards respiratory distress syndrome progress and liver enzyme: 1
- acute lung injury and adaptive immune response: 1, 2, 3, 4, 5
- acute lung injury and adjuvant therapy: 1, 2, 3, 4
- acute lung injury and adjuvant treatment: 1, 2
- acute lung injury and administration route: 1, 2
- acute respiratory syndrome and adjuvant agent: 1
- acute respiratory syndrome and adjuvant consider: 1
- acute respiratory syndrome and adjuvant therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and adjuvant treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and liver enzyme elevation: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date